Eli Lilly and Company (NYSE:LLY) Reaches New 12-Month Low - What's Next?

Key Points

• Eli Lilly's stock price hit a new 12-month low at $637.07, down from a previous close of $746.37, with significant trading volume of over 7.7 million shares.
• Analysts have mixed ratings for Eli Lilly, with target prices ranging from $700.00 to $1,050.00, reflecting concerns and optimism about the company's performance.
• The company recently reported $6.31 earnings per share, exceeding expectations, and announced a quarterly dividend of $1.50 per share, indicating continued financial strength despite stock price declines.

Eli Lilly and Company (NYSE:LLY - Get Free Report)'s stock price reached a new 52-week low on Thursday . The company traded as low as $639.39 and last traded at $637.07, with a volume of 7711396 shares trading hands. The stock had previously closed at $746.37.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. UBS Group reduced their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Leerink Partners reissued a "market perform" rating and set a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday. Guggenheim raised their price target on Eli Lilly and Company from $936.00 to $942.00 and gave the company a "buy" rating in a report on Friday, July 11th. HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their price target for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. Finally, Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 target price for the company. One research analyst has rated the stock with a sell rating, four have given a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $999.50.

Eli Lilly and Company Stock Down 14.3%

The firm's 50-day moving average price is $777.97 and its 200 day moving average price is $800.20. The firm has a market cap of $606.31 billion, a P/E ratio of 52.13, a PEG ratio of 1.09 and a beta of 0.44. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The firm's revenue for the quarter was up 37.6% on a year-over-year basis. During the same period last year, the company earned $3.92 earnings per share. On average, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is currently 48.82%.

Institutional Investors Weigh In On Eli Lilly and Company

Several large investors have recently made changes to their positions in the company. WestEnd Advisors LLC grew its stake in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after buying an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC acquired a new position in shares of Eli Lilly and Company in the first quarter valued at $27,000. Blume Capital Management Inc. lifted its position in Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company's stock worth $34,000 after purchasing an additional 14 shares during the period. Citizens National Bank Trust Department boosted its stake in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after buying an additional 27 shares in the last quarter. Finally, IMG Wealth Management Inc. bought a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $35,000. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.